Reprogramming of Fatty Acid Metabolism via PPARα-Orchestrated FADS2 in Keratinocytes Modulates Skin Inflammation in Psoriasis
- Adv Sci (Weinh). 2025 Aug 29:e17049. doi: 10.1002/advs.202417049.
- 1. Department of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
- 2. Department of Dermatology, Shanghai Tenth People's Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200072, China.
Psoriasis is a chronic inflammatory skin disorder characterized by keratinocyte hyper-proliferation and immune dysregulation. Recent evidence has implicated dysregulated polyunsaturated fatty acid (PUFA) metabolism in its pathogenesis. In this study, fatty acid desaturase 2 (FADS2), the rate-limiting Δ6-desaturase in PUFA biosynthesis, is identified as a central regulator of psoriatic inflammation. FADS2 expression is consistently reduced in keratinocytes from patients with psoriasis and in mouse models. Keratinocyte-intrinsic Fads2 knockdown exacerbates imiquimod-induced psoriasis-like dermatitis, which is marked by enhanced neutrophil recruitment and NF-κB activation, whereas Fads2 overexpression exerts protective effects and alleviates skin inflammation. In vitro, FADS2 knockdown in keratinocytes enhances M5-induced pro-inflammatory cytokine production, whereas FADS2 overexpression attenuates these effects. Lipidomic analysis reveals that impaired docosahexaenoic acid (DHA) biosynthesis is a key downstream consequence of FADS2 deficiency. Mechanistically, loss of FADS2 disrupts DHA biosynthesis, thus promoting an inflammatory response accompanied by increased NF-κB phosphorylation in keratinocytes to attract neutrophils. Furthermore, PPARα is identified as an upstream transcriptional activator of FADS2, and pharmacological activation of PPARα alleviates psoriatic inflammation in a FADS2-dependent manner. Together, these findings uncover a PPARα-FADS2-DHA-NF-κB axis that links lipid metabolism to immune regulation in psoriasis, highlighting a potential therapeutic strategy for restoring cutaneous immune homeostasis.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-
target: Endogenous Metabolite
-
target: PPAR